# US 12,594,271 B2 · Combination therapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,271 B2
- Document ID: US12594271B2
- Status: Granted
- Kind: B2
- Application number: 17/773,838
- Filed: 2020-11-05
- Published: 2022-12-15
- Granted: 2026-04-07
- Earliest claimed: 2019-11-05
- Assignees: Health Research, Inc.
- Applicants: Health Research, Inc.
- Inventors: Scott I. Abrams; Sean H. Colligan
- Web page: https://patentgrep.com/patent/US12594271B2

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- C07K 16/2818: {against CD28 or CD152}
- A61K 31/4353: ortho- or peri-condensed with heterocyclic ring systems
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.

## Claims

### Claim 1

A method for alleviation of acute and chronic signs and symptoms associated with a cancer selected from a group consisting of breast, lung, renal, colorectal, cervical, gastric, ovarian, prostate, pancreatic cancer, or melanoma, the method comprising administering an anti-PD-1 antibody to the individual diagnosed with a said cancer, the method further comprising administering brequinar to the individual to inhibit development of myeloid-derived suppressor cells (MDSC) burden by reducing the frequency of granulocyte progenitors and increasing the frequency of monocyte progenitors in bone marrow of the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody is pembrolizumab.

### Claim 3 (depends on 2)

The method of claim 2, wherein the breast cancer is triple negative breast cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the breast cancer is refractory to chemotherapy, hormonal treatment, radiation, or surgical treatment.

### Claim 5 (depends on 3)

The method of claim 3, wherein the breast cancer is metastatic triple-negative breast cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein metastasis of the cancer is also inhibited, and wherein the cancer is refractory to immune checkpoint blockade.